| P2093 | author name string | Alastair Carruthers | |
| | Jean Carruthers | |
| P2860 | cites work | Chinese Journal of Tuberculosis and Respiratory Diseases | Q27710354 |
| | A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement | Q28205185 |
| | Botulinum B treatment of the glabellar and frontalis regions: a dose response analysis | Q30736752 |
| | Effect of botulinum toxin type A on movement-associated rhytides following CO2 laser resurfacing | Q30741117 |
| | Effect of botulinum toxin pretreatment on laser resurfacing results: a prospective, randomized, blinded trial | Q31000327 |
| | Botulinum toxin A in the mid and lower face and neck | Q31084088 |
| | The adjunctive usage of botulinum toxin | Q31963601 |
| | The evolution of botulinum neurotoxin type A for cosmetic applications | Q33296171 |
| | Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology | Q33385497 |
| | Adverse effects associated with facial application of botulinum toxin: a systematic review with meta-analysis | Q33402945 |
| | Botulinum Toxin Injection into Extraocular Muscles as an Alternative to Strabismus Surgery | Q34282549 |
| | Botulinum toxin type A: history and current cosmetic use in the upper face | Q34320281 |
| | Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases | Q34444412 |
| | Raising eyebrows with botulinum toxin | Q78197176 |
| | Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period | Q78609665 |
| | Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy | Q79720061 |
| | Botulinum toxin to improve facial wound healing: A prospective, blinded, placebo-controlled study | Q80091137 |
| | Effects of Botox and Neuronox on muscle force generation in mice | Q80546567 |
| | Potency of the botulinum toxin product CNBTX-A significantly exceeds labeled units in standard potency test | Q80720244 |
| | Long-distance retrograde effects of botulinum neurotoxin A | Q81006671 |
| | A comparison of two botulinum type a toxin preparations for the treatment of glabellar lines: double-blind, randomized, pilot study | Q81593350 |
| | Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm | Q81858301 |
| | Botulinum toxin products overview | Q82022191 |
| | Nonsurgical reshaping of the lower face | Q82972112 |
| | Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. | Q34560643 |
| | Treatment of Glabellar Frown Lines with C. Botulinum-A Exotoxin | Q34615234 |
| | Botulinum a exotoxin for hyperfunctional facial lines: where not to inject | Q34841554 |
| | Complications, adverse reactions, and insights with the use of botulinum toxin | Q35129638 |
| | Botulinum neurotoxin type B--a rapid wrinkle reducer | Q35183528 |
| | Safety of botulinum toxin type A: a systematic review and meta-analysis | Q35841671 |
| | Combination therapy with BOTOX and fillers: the new rejuvnation paradigm | Q36511410 |
| | Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients | Q36714530 |
| | Botulinum toxins for facial wrinkles: beyond glabellar lines | Q36743299 |
| | Complications of botulinum toxin type A. | Q36743303 |
| | Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia | Q36770303 |
| | The use of botulinum toxin A in perioral rejuvenation | Q37001863 |
| | Early communication about an ongoing safety review Botox and Botox Cosmetic (botulinum toxin type A) and Myobloc (botulinum toxin type B). | Q37270340 |
| | A comprehensive review of patient-reported satisfaction with botulinum toxin type a for aesthetic procedures | Q37339642 |
| | Botulinum toxin to minimize facial scarring | Q40662714 |
| | Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. | Q43700072 |
| | Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia | Q44394591 |
| | Chemical browlift | Q45136559 |
| | Eyebrow height after botulinum toxin type A to the glabella | Q45748753 |
| | Cosmetic uses of botulinum toxins for lower aspects of the face and neck | Q46068402 |
| | Lower facial contouring with botulinum toxin type A. | Q46189135 |
| | Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study | Q46296695 |
| | The effect of botulinum toxin type A on full-face intense pulsed light treatment: a randomized, double-blind, split-face study | Q46472401 |
| | Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study | Q46768465 |
| | Sarcoidal granulomas following injections of botulic toxin A (Botox) for corrections of wrinkles | Q46958716 |
| | Botox and collagen for glabellar furrows: advantages of combination therapy | Q47733894 |
| | The effect of full-face broadband light treatments alone and in combination with bilateral crow's feet Botulinum toxin type A chemodenervation | Q47981938 |
| | Use of botulinum toxin type A to prevent widening of facial scars. | Q53246841 |
| | Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. | Q53503162 |
| | The use of botulinum toxin type A in aesthetic mandibular contouring. | Q53625993 |
| | Botulinum Toxin Type A Treatment for Contouring of the Lower Face | Q53652284 |
| | Long-term botulinum toxin efficacy, safety, and immunogenicity. | Q54782341 |
| | [Pharmacological aspects of therapeutic botulinum toxin preparations]. | Q55042153 |
| | Botulinum toxin for the treatment of hyperfunctional lines of the face | Q72894311 |
| | Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion | Q73405092 |
| | Deep resting glabellar rhytides respond to BTX-A and Hylan B | Q73405114 |
| | Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment | Q73526811 |
| | A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects | Q73666865 |
| | [Bruxism, temporo-mandibular dysfunction and botulinum toxin] | Q73827379 |
| | Botulinum A toxin (BOTOX) in the lower eyelid: dose-finding study | Q73832148 |
| | Idiosyncratic adverse reactions to intramuscular botulinum toxin type A injection | Q73942348 |
| | Comparison of Botox with a Chinese type A botulinum toxin | Q77446738 |
| | Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery | Q78019574 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 571-82, ix | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Obstetrics and Gynecology Clinics of North America | Q15750118 |
| P1476 | title | Botulinum toxin in facial rejuvenation: an update | |
| | Botulinum Toxin in Facial Rejuvenation: An Update | |
| P478 | volume | 37 | |